📰 Code Therapeutics News
Page 2 - Code Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Code Therapeutics. Real-time updates on events, politics, business and more.
March 28, 2024
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. RNAZ, the RNA oncology company committed to more effectively treating cancer using RNA…
February 20, 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--Feb 20, 2024--
January 31, 2024
31.01.2024 - BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) - TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from ... Seite 1
January 29, 2024
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement
January 24, 2024
Verve Therapeutics (NASDAQ:VERV – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Valuation and Earnings This table compares Verve […]
January 23, 2024
BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the
January 19, 2024
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
January 18, 2024
By Colin Kellaher TransCode Therapeutics shares fell sharply on Thursday after the RNA oncology company filed with the U.S. Securities and Exchange...
January 18, 2024
By Josh Beckerman TransCode Therapeutics shares were recently down 49% to $1.10 after the pricing of a $7.25 million public offering. Shares fell to a...